Kleo Pharmaceuticals names chief scientific officer
Dr. Grosso brings over 15 years of scientific leadership and experience in advancing immunotherapies through clinical development and has worked on some of the most successful new entrants in the field including nivolumab (Opdivo) and ipilimumab (Yervoy).
Prior to joining Kleo, Dr. Grosso served as Director of Immuno-Oncology at Celgene and focused on the clinical development of immuno-oncology platforms, including CAR-T cells.
Prior to Celgene, Dr. Grosso was at Bristol-Myers Squibb, where he served on the nivolumab (Opdivo) clinical development team and focused on designing biomarker-intensive clinical trials in novel oncology indications, leading the biomarker effort for nivolumab (Opdivo) and other IO assets across multiple solid and hematological indications.
He was also involved in the design and implementation of the BMS-sponsored International Immuno-Oncology Network.
Dr. Grosso received his B.S. in Microbiology and Immunology at the University of Rochester. He earned his Ph.D. in Microbiology and Immunology from the University of Miami.
He conducted his post-doctoral training on novel checkpoint molecules, including LAG-3 and PD-1, in tumor tolerance models at John Hopkins University School of Medicine.